Samsung to Double AI-Powered Mobile Devices with Google Gemini in Global AI Race 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
Chinese EV Stocks Slide as December Sales Growth Slows, Raising Demand Concerns 
BTIG Initiates Buy on SoftBank as AI and Robotics Strategy Gains Momentum 
Dell Revives XPS Laptop Lineup With New XPS 14 and XPS 16 to Boost Premium PC Demand 
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
Samsung Electronics Hits Record High as AI Momentum Fuels Investor Optimism 
Embraer Boosts Aircraft Deliveries in Q4 2025, Signaling Strong Growth Into 2026 
Lenovo Unveils AI Cloud Gigafactory With NVIDIA and Launches New AI Platform at CES 2026 
Tesla UK Sales Slide as Competition Intensifies, While BYD Surges in Electric Vehicle Market 
Tokyo Electric Power Shares Surge as Kashiwazaki-Kariwa Nuclear Reactor Restart Nears 
L3Harris Nears $500M Deal to Sell Majority Stake in Space Propulsion Portfolio to AE Industrial 
AMD Unveils Next-Generation AI and PC Chips at CES, Highlights Major OpenAI Partnership 
SGH’s A$13.15 Billion BlueScope Bid Sparks Steel Sector Shake-Up and Share Price Surge 
Cathay Pacific Shares in Focus as Air China Plans Major Stake Reduction 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
SMIC Shares Climb as China Boosts Chipmaking Support Amid AI Optimism 
GAITHERSBURG, Md., April 04, 2016 -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Iksung Cho has been named Vice President, Biostatistics.
Mr. Cho joined Novavax in December 2015 as Executive Director, Biostatistics with responsibility for coordinating statistical and statistical programming activities for vaccine candidates in various stages of clinical development. Prior to joining Novavax he was Senior Statistician at PATH, an international nonprofit organization that aims to accelerate innovation across vaccines, drugs, diagnostics, devices and system and service innovations.
Mr. Cho’s experience includes positions of increasing responsibility in biostatistics and data management at Aviron, Merck and MedImmune, where he was Vice President of Global Biostatistics. He earned Master’s degrees in both statistics and applied mathematics from Virginia Polytechnic and State University and completed graduate studies in mathematics.
“Iksung has rapidly become a critical part of our team,” said Gregory M. Glenn, M.D., President, Research and Development. “We expect to leverage his deep experience in biostatistics to evaluate important data readouts from the pivotal Phase 3 Resolve trial of our RSV F Vaccine in older adults and the Phase 2 rollover trial in older adults later this year.”
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271
